Pharmaceutical Technology

APRIL 7, 2023

In vitro data of EDP-323 showed a significant reduction in RSV replication with picomolar potency in primary human bronchial epithelial cells against RSV A and B. We believe this designation will be a valuable component of our clinical and regulatory strategy as we progress EDP-323 in development.”

In-Vitro 276

In-Vitro Bioavailability Development Drugs 276

Drug Discovery World

JANUARY 18, 2023

The system will initially be investigated for improving the preclinical estimation of human drug bioavailability compared to standard animal models. . We are working hard to evidence how our technology can tackle these critical drug development bottlenecks and lead the way towards inclusion of OOC/MPS data within IND submissions.” .

Bioavailability 52

Bioavailability In-Vitro Research Drugs 52

Camargo

FEBRUARY 10, 2021

Drug development is an extremely cumbersome process, requiring the testing of an agent from in vitro studies to in vivo studies to in silico modeling. Proper planning of PK assessments can accelerate the development of both novel drugs and new formulations of previously approved drugs developed via the 505(b)(2) pathway.

Production 133

Production Bioavailability In-Vivo Bioequivalency 133

pharmaphorum

NOVEMBER 9, 2022

A pre-clinical pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability pore (mPTP) are to be developed. A £16 million Series A financing – led by Omega Funds – has been announced by the innovative neuroscience company NRG Therapeutics Ltd., It has been supporting NRG’s work since 2019.

In-Vitro 52

In-Vitro Bioavailability Medicine Clinical Trials 52

Drug Discovery World

AUGUST 3, 2022

Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake. Over the years, a range of different CPPs have been developed, including natural translocating proteins through to newly-designed computer-prediction sequences 3.

Bioavailability 52

Bioavailability In-Vivo RNA In-Vitro 52

The Pharma Data

DECEMBER 9, 2020

Liebisch , Vigil Neuroscience is developing a pipeline of precision-based therapies to combat both rare and common neurodegenerative diseases by restoring the vigilance of microglia. It will if the following five companies, which all launched this year with Series A financing, have anything to say about it. . Vigil Neuroscience.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

The Pharma Data

OCTOBER 21, 2020

We designed KB-0742 to be an orally bioavailable CDK9 inhibitor with a differentiated selectivity profile,” said Norbert Bischofberger, Ph.D., We look forward to advancing clinical development of KB-0742 to establish the dose, safety and efficacy of this investigational therapy as a potential treatment for MYC-amplified tumors.”.

In-Vivo 40

In-Vivo In-Vitro Bioavailability Clinical Trials 40